- Home
- OTLK vs SNAL Comparison
OTLK vs SNAL Comparison
Compare OTLK & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- SNAL
- Stock Information
- Founded
- OTLK 2010
- SNAL 2000
- Country
- OTLK United States
- SNAL United States
- Employees
- OTLK N/A
- SNAL N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- SNAL Computer Software: Prepackaged Software
- Sector
- OTLK Health Care
- SNAL Technology
- Exchange
- OTLK Nasdaq
- SNAL Nasdaq
- Market Cap
- OTLK 48.3M
- SNAL 40.0M
- IPO Year
- OTLK 2016
- SNAL 2022
- Fundamental
- Price
- OTLK $1.77
- SNAL $0.91
- Analyst Decision
- OTLK Strong Buy
- SNAL
- Analyst Count
- OTLK 5
- SNAL 0
- Target Price
- OTLK $10.20
- SNAL N/A
- AVG Volume (30 Days)
- OTLK 689.4K
- SNAL 33.0K
- Earning Date
- OTLK 05-15-2025
- SNAL 05-14-2025
- Dividend Yield
- OTLK N/A
- SNAL N/A
- EPS Growth
- OTLK N/A
- SNAL N/A
- EPS
- OTLK 0.83
- SNAL 0.04
- Revenue
- OTLK N/A
- SNAL $90,462,190.00
- Revenue This Year
- OTLK N/A
- SNAL $21.96
- Revenue Next Year
- OTLK $288.46
- SNAL $22.77
- P/E Ratio
- OTLK $2.12
- SNAL $24.31
- Revenue Growth
- OTLK N/A
- SNAL 46.95
- 52 Week Low
- OTLK $0.87
- SNAL $0.52
- 52 Week High
- OTLK $9.25
- SNAL $3.42
- Technical
- Relative Strength Index (RSI)
- OTLK 57.64
- SNAL 42.01
- Support Level
- OTLK $1.55
- SNAL $0.85
- Resistance Level
- OTLK $1.90
- SNAL $0.97
- Average True Range (ATR)
- OTLK 0.18
- SNAL 0.07
- MACD
- OTLK 0.01
- SNAL -0.00
- Stochastic Oscillator
- OTLK 53.10
- SNAL 17.14
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.